Canada Moves to Boost Biosimilar Market

Executive Summary Biosimilar uptake in Canada is expected to benefit from moves to switch patients onto biosimilars and the removal of health technology appraisal reviews from the process for listing drugs on public plans.
  • Francesca Bruce

Executive Summary

Biosimilar uptake in Canada is expected to benefit from moves to switch patients onto biosimilars and the removal of health technology appraisal reviews from the process for listing drugs on public plans.

CanadaFlag
Source: pink.pharmaintelligence.informa.com